FILE PHOTO: Vials of a COVID-19 vaccine candidate, a recombinant adenovirus vaccine named Ad5-nCoV, co-developed by Chinese biopharmaceutical firm CanSino Biologics Inc and a team led by Chinese military infectious disease expert, are pictured in Wuhan, Hubei province, China March 24, 2020. China Daily via REUTERS
MOSCOW (Reuters) - Russian pharmaceutical company Petrovax on Thursday said 92.5% of Russian volunteers in trials of the Chinese Ad5-Ncov vaccine against COVID-19 had shown high levels of antibodies, the Interfax news agency reported.
Ad5-nCoV is a candidate vaccine co-developed by CanSino Biologics and a Chinese military-backed research unit.
Already a subscriber? Log in.
Subscribe or renew your subscriptions to win prizes worth up to RM68,000!
Cancel anytime. No ads. Auto-renewal. Unlimited access to the web and app. Personalised features. Members rewards.
